| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5548890 | Neuropharmacology | 2017 | 63 Pages |
Abstract
These results could be of clinical relevance, as they suggest BNN-20 as an important neuroprotective agent acting through the TrkB neurotrophin receptor pathway, mimicking the action of the endogenous neurotrophin BDNF. Thus BNN-20 could be proposed for treatment of PD.
Keywords
CSCDHEAMDADHEA-SdorsomedialventromedialARG1TrkBDOPACNGFdehydroepiandrosteroneDATiNOSRODNACGSHBDNFN-acetylcysteineventrolateral ArginaseDopamine transporterParkinson's diseaserelative optical densitytropomyosin receptor kinase Bsubstantia nigra pars compactatyrosine hydroxylasedorsolateralDopamineBBBdehydroepiandrosterone sulfatenerve growth factormalondialdehydeblood-brain-barrierNeuroprotectionnitric oxide synthasehomovanillic acidHVACaffeinehigh-performance liquid chromatographyHPLCGlutathione
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Konstantinos Botsakis, Theodora Mourtzi, Vasiliki Panagiotakopoulou, Malamati Vreka, Georgios T. Stathopoulos, Iosif Pediaditakis, Ioannis Charalampopoulos, Achilleas Gravanis, Foteini Delis, Katerina Antoniou, Dimitrios Zisimopoulos,